Telmitan® Max
Amlodipine + Telmisartan BP

Description:
It is a combination of Calcium Channel Blocker (CCB) & Angiotensin Receptor Blocker (ARB).

Mode of Action:
Telmisartan blocks the vasoconstrictor and aldosterone-secreting effects of angiotensin II by selectively blocking the binding of angiotensin II to the AT1 receptor in many tissues, such as vascular smooth muscle and the adrenal gland. And Amlodipine is a dihydropyridine calcium channel blocker that inhibits the transmembrane influx of calcium ions into vascular smooth muscle and cardiac muscle.

Pharmacokinetics:
Absorption: Absolute bioavailability of Telmisartan is 43%. The bioavailability of amlodipine is 64-90%. ***Distribution:*** Volume of distribution of Telmisartan & Amlodipine is 500L & 21 L/kg respectively. ***Metabolism:*** Telmisartan is minimally metabolized by conjugation to form a pharmacologically inactive acyl glucuronide. The cytochrome P450 isoenzymes are not involved in the metabolism of Telmisartan. Amlodipine is heavily (approximately 90%) converted to inactive metabolites via hepatic breakdown with 10% of the parent compound and 60% of the metabolites found excreted in the urine. ***Elimination:*** Most of the administered Telmisartan (>97%) is eliminated unchanged in feces via biliary excretion. Amlodipine is 10% excreted as unchanged drug in the urine.

Composition:
Telmitan® Max 5/40 mg Tablet: Each film-coated tablet contains Amlodipine Besilate BP 6.932 mg equivalent to Amlodipine 5 mg & Telmisartan BP 40 mg.
Telmitan® Max 5/80 mg Tablet: Each film-coated tablet contains Amlodipine Besilate BP 6.932 mg equivalent to Amlodipine 5 mg & Telmisartan BP 80 mg.
Telmitan® Max 10/40 mg Tablet: Each film-coated tablet contains Amlodipine Besilate BP 13.862 mg equivalent to Amlodipine 10 mg & Telmisartan BP 40 mg.
Telmitan® Max 10/80 mg Tablet: Each film-coated tablet contains Amlodipine Besilate BP 13.862 mg equivalent to Amlodipine 10 mg & Telmisartan BP 80 mg.

Indication:
This combination is indicated for essential hypertension & uncontrolled hypertension.

Dosage & Administration:
Initial dose in 5/40 mg or 5/80 mg once daily. Dosage may be increased after at least 2 weeks to a maximum dose of 10/80 mg once daily.

Contraindication:
This combination is contraindicated for the patients who have sensitivity to this product or any to its components pregnancy, lactation, biliary obstructive disorders, severe hepatic impairment, hypotension, cardiogenic shock, left ventricle outflow tract obstruction etc.

Side-effects:
The most common reasons for discontinuation of this combination are peripheral edema, dizziness, and hypotension etc.

Use in Pregnancy & Lactation:
Pregnancy
This combination should be discontinued during pregnancy.

Lactation

Data for the use of this combination for lactating mother is not found.

Precaution:
Discontinue this combination as soon as possible. In case of hypotension, start treatment under close medical supervision with a reduced dose.

Drug interaction:
This combination shows drug-drug interaction with Digoxin, lithium, Ramipril.

Overdose:
Limited data are available with regard to overdose of this combination in humans.

Storage:
Store in a cool (Below 25˚ C temperature) and dry place protected from light.

Packaging:
Telmitan® Max 5/40 mg Tablet: Each box contains 14x2Tablets in Alu-Alu Blister Pack.
Telmitan® Max 5/80 mg Tablet: Each box contains 14x1Tablets in Alu-Alu Blister Pack.
Telmitan® Max 10/40 mg Tablet: Each box contains 14x2Tablets in Alu-Alu Blister Pack.
Telmitan® Max 10/80 mg Tablet: Each box contains 14x1Tablets in Alu-Alu Blister Pack.